Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular dystrophy ("Duchenne") and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne and LGMD.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q2 2026 · $230.6MThe company’s own SEC segment disclosure.
- United States$198.6M86%
- Non Us$32.0M14%
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $731M in Q1 2026 (quarter ended March 31, 2026), down 1.9% from the same quarter a year earlier. That came with net income of $331M (45% of revenue). For the full year FY2025, revenue was $2.20B (+16% year on year) and net income −$713M. Its largest region in 2026-Q2 was United States at $199M, 86% of the disclosed total, just ahead of Non Us at 14%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.